Literature DB >> 17575366

Acromegaly associated with type 2 diabetes showing normal IGF-1 levels under poorly controlled glycemia.

Dong Jun Lim1, Hyuk Sang Kwon, Jae Hyoung Cho, Sang Hee Kim, Yoon Hee Choi, Kun Ho Yoon, Bong Yun Cha, Kwang Woo Lee, Ho Young Son, Sung Koo Kang.   

Abstract

Acromegaly is caused by excessive secretion of growth hormone (GH), and a resultant persistent elevation of insulin-like growth factor-1 (IGF-1) levels. Diabetes mellitus is accompanied in some acromegalic patients with insulin resistance. We encountered a type-2 diabetic patient who had a poorly controlled glycemic state and was diagnosed as acromegaly with normal IGF-1 levels. The patient showed definite acromegalic features. However, in the first screening test, GH levels were high and IGF-1 levels were inappropriately normal so the results were not close to the diagnosis of acromegaly. After moderate glycemic control, an oral glucose suppression test was performed, showing no suppressed GH response. TRH test revealed paradoxical increases in growth hormone levels and a brain MRI discovered a pituitary adenoma. After several-months insulin treatment, IGF-1 levels were increased to the abnormal state and GH levels were decreased without treatment for acromegaly. Here we report the rare case of acromegaly that presents inappropriately normal IGF-1 levels at the time of diagnosis in uncontrolled type 2 diabetic patient and shows increased IGF-1 levels after glycemic control with insulin therapy. When evaluating acromegaly in type 2 diabetes under poorly controlled glycemia, cautious IGF-1 analysis is needed after sufficient glycemic control.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17575366     DOI: 10.1507/endocrj.k06-083

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  6 in total

1.  What the mind knows but the eyes may still miss: reducing the 'Acromegalic Window'.

Authors:  Parijat De; Danielle R G Foucault
Journal:  BMJ Case Rep       Date:  2014-05-26

2.  Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism?

Authors:  Georgiana Dobri; Soamsiri Niwattisaiwong; James F Bena; Manjula Gupta; John Kirwan; Lawrence Kennedy; Amir H Hamrahian
Journal:  Endocrine       Date:  2018-11-10       Impact factor: 3.633

3.  Frequency of acromegaly in adults with diabetes or glucose intolerance and estimated prevalence in the general population.

Authors:  Pedro Weslley Rosario
Journal:  Pituitary       Date:  2011-09       Impact factor: 4.107

Review 4.  Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly.

Authors:  Laure Cazabat; Jean-Claude Souberbielle; Philippe Chanson
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 5.  Discordance between growth hormone and insulin-like growth factor-1 after pituitary surgery for acromegaly: a stepwise approach and management.

Authors:  Mehdi Zeinalizadeh; Zohreh Habibi; Juan C Fernandez-Miranda; Paul A Gardner; Steven P Hodak; Sue M Challinor
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

6.  Acromegaly with Normal Insulin-Like Growth Factor-1 Levels and Congestive Heart Failure as the First Clinical Manifestation.

Authors:  Hyae Min Lee; Sun Hee Lee; In Ho Yang; In Kyoung Hwang; You Cheol Hwang; Kyu Jeung Ahn; Ho Yeon Chung; Hui Jeong Hwang; In Kyung Jeong
Journal:  Endocrinol Metab (Seoul)       Date:  2015-09-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.